Mereo Historical Financial Ratios
| MREO Stock | USD 3.35 0.06 1.82% |
Mereo BioPharma is lately reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 129 will help investors to properly organize and evaluate Mereo BioPharma Group financial condition quickly.
Mereo |
About Mereo Financial Ratios Analysis
Mereo BioPharma GroupFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Mereo BioPharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Mereo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Mereo BioPharma history.
Mereo BioPharma Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Mereo BioPharma Group stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Mereo BioPharma sales, a figure that is much harder to manipulate than other Mereo BioPharma Group multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Mereo BioPharma Group. There are two different methods for calculating Mereo BioPharma Group invested capital: operating approach and financing approach. Understanding Mereo BioPharma invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Mereo BioPharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Mereo BioPharma Group current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Mereo BioPharma's Current Ratio is very stable compared to the past year. As of the 21st of December 2024, Debt To Equity is likely to grow to 0.11, while Price To Sales Ratio is likely to drop 135.14.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 0.3 | 0.36 | 0.28 | 0.26 | Receivables Turnover | 25.7 | 0.55 | 2.68 | 2.55 |
Mereo BioPharma fundamentals Correlations
Click cells to compare fundamentals
Mereo BioPharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mereo BioPharma fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 7.28 | (80.76) | 9.6 | 7.31 | 30.14 | 31.65 | |
| Book Value Per Share | 0.45 | (0.0443) | 0.17 | 0.1 | 0.0766 | 0.0728 | |
| Free Cash Flow Yield | (0.16) | (0.0235) | (0.006837) | (0.0858) | (0.0141) | (0.0149) | |
| Operating Cash Flow Per Share | (0.51) | (0.0839) | (0.009926) | (0.0644) | (0.032) | (0.0336) | |
| Capex To Depreciation | 0.0133 | 0.01 | 0.83 | 0.0138 | 0.39 | 0.38 | |
| Pb Ratio | 7.28 | (80.76) | 9.6 | 7.31 | 30.14 | 31.65 | |
| Free Cash Flow Per Share | (0.51) | (0.084) | (0.0109) | (0.0644) | (0.0327) | (0.0343) | |
| Roic | (0.54) | (31.54) | (0.21) | (0.57) | (0.51) | (0.53) | |
| Inventory Turnover | (1.97) | (3.52) | (9.84) | (0.35) | (0.32) | (0.33) | |
| Net Income Per Share | (0.39) | (0.48) | 0.0241 | (0.0567) | (0.0447) | (0.0469) | |
| Days Of Inventory On Hand | (185.17) | (103.56) | (37.1) | (1.0K) | (1.2K) | (1.1K) | |
| Payables Turnover | 4.01 | 5.57 | 7.84 | 0.27 | 1.1 | 1.04 | |
| Cash Per Share | 0.39 | 0.19 | 0.0711 | 0.18 | 0.0871 | 0.0827 | |
| Pocfratio | (6.38) | (42.66) | (161.2) | (11.65) | (72.09) | (75.69) | |
| Interest Coverage | (11.3) | (5.89) | (5.23) | (12.96) | (9.86) | (10.36) | |
| Capex To Operating Cash Flow | (4.57E-4) | (5.65E-4) | (0.1) | (2.58E-4) | (0.0198) | (0.0208) | |
| Pfcf Ratio | (6.38) | (42.64) | (146.26) | (11.65) | (70.69) | (74.22) | |
| Days Payables Outstanding | 90.92 | 65.56 | 46.57 | 1.4K | 332.67 | 203.31 | |
| Income Quality | 1.12 | 0.17 | (0.37) | 1.08 | 0.72 | 0.66 | |
| Roe | (0.98) | (0.87) | 10.93 | 0.14 | (0.55) | (0.58) | |
| Ev To Operating Cash Flow | (6.73) | (42.46) | (146.4) | (10.53) | (69.65) | (73.13) | |
| Pe Ratio | (8.41) | (7.39) | 66.37 | (13.23) | (51.7) | (49.11) | |
| Return On Tangible Assets | (0.92) | (0.83) | (5.23) | 0.12 | (0.53) | (0.45) | |
| Ev To Free Cash Flow | (6.73) | (42.44) | (132.83) | (10.53) | (68.3) | (71.71) | |
| Earnings Yield | (0.12) | (0.14) | 0.0151 | (0.0756) | (0.0193) | (0.0203) | |
| Intangibles To Total Assets | 0.51 | 0.5 | 0.19 | 0.27 | 0.0164 | 0.0156 | |
| Net Debt To E B I T D A | (0.43) | 0.15 | 15.5 | 1.04 | 1.98 | 2.03 | |
| Current Ratio | 1.02 | 3.47 | 7.92 | 2.52 | 6.72 | 9.55 | |
| Tangible Book Value Per Share | (0.047) | (0.14) | 0.12 | 0.0626 | 0.075 | 0.0712 | |
| Graham Number | 1.99 | 0.7 | 0.3 | 0.36 | 0.28 | 0.26 | |
| Shareholders Equity Per Share | 0.45 | (0.0443) | 0.17 | 0.1 | 0.0766 | 0.0728 | |
| Debt To Equity | 0.66 | 0.55 | (1.08) | 0.18 | 0.0869 | 0.11 |
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Mereo Stock
Moving against Mereo Stock
| 0.82 | VCEL | Vericel Corp Ord | PairCorr |
| 0.76 | VCYT | Veracyte | PairCorr |
| 0.7 | DRTS | Alpha Tau Medical | PairCorr |
| 0.56 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
| 0.55 | SABSW | SAB Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.